News | March 26, 2022
NATHEALTH 8th annual summit in New Delhi from March 28-29.
More than 120 speakers and 5,000 delegates are expected to attend
More than 120 speakers and 5,000 delegates are expected to attend
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
Data to establish the safety profile and human dose of vaccine candidate
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Prof. Kypros has revolutionised the field of fetal medicine through his extensive research and medical practice achievements, including introducing intrauterine blood transfusions for fetal anaemia
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
